---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-007579"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:18:51.629876+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lyell reports Q4 net loss $52.9M, full-year loss $234.6M; cash $562.7M supports pipeline into 2027

## Summary
- Net loss $52.9M in Q4 2023 and $234.6M full year; non-GAAP net loss $43.9M Q4 and $177.4M FY.
- Revenue $0.1M in FY2023 vs $84.7M in FY2022 due to termination of GSK collaboration in Dec 2022.
- Cash $562.7M as of Dec 31, 2023; expected to fund operations into 2027.
- Expect initial clinical data from LYL797 CAR T in H1 2024 and LYL845 TIL in H2 2024; LYL845 got FDA Orphan Drug Designation for melanoma.
- Appointed Matt Lang as Chief Business Officer; IND submission for LYL119 expected H1 2024.

## SEC filing metadata
- accession: 0001628280-24-007579
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828024007579/0001628280-24-007579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828024007579/lyel-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-007579
- JSON: https://secwatch.observer/filing/0001628280-24-007579.json
- Plain text: https://secwatch.observer/filing/0001628280-24-007579.txt

## Key facts
- Earnings Releases
  Lyell Immunopharma, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $52.9 million.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: $52.9 million
  - Result: reported results
  source text: Fourth Quarter and Full Year 2023 Financial Results Lyell reported a net loss of $52.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000162828024007579/0001628280-24-007579-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.